Literature DB >> 20857144

Parental reports of adverse events following simultaneously given dT-IPV and MMR vaccines in healthy 9-year-old children.

Jeanet M Kemmeren1, Nicoline A T van der Maas, Hester E de Melker.   

Abstract

In the Netherlands, children at 9 years of age receive a booster dT-IPV together with their second measles, mumps, and rubella (MMR) vaccination within the national immunization program. Safety is monitored continuously by enhanced passive surveillance. This population-based study was conducted to obtain more information on adverse events after vaccination at 9 years of age. Questionnaires on local and systemic reactions were distributed 1 and 3 weeks after vaccination, respectively, to parents of 1,250 healthy children who received their MMR and diphtheria, tetanus, and inactivated poliovirus injection (dT-IPV) vaccination as scheduled. Response to the questionnaires was 57.0% and 46.5%, respectively. Local reactions occurred in 86.5% of the children within 7 days after vaccination, more often at the dT-IPV (83.4%) than at the MMR site (32.7%). Pain was the most reported symptom (80.8% at the dT-IPV site; 29.1% at the MMR site). Systemic events occurred in 33.4% children within 7 days after vaccination, with headache as the most frequently reported (20.8%). Systemic events occurred in 20.8% children 8-21 days after vaccination. Children with local reactions at only the dT-IPV site had significantly more systemic events (19.3%) than those without local reactions (3.4%, p < 0.01). Such difference was not found for the MMR site. No serious adverse events were reported. Medical intervention was applied to 133 children (130 used analgesics and for three children the GP was consulted by phone). In conclusion, the frequency of reported local reactions is high, especially at the dT-IPV site, but all symptoms were transient. However, the use of reduced antigen content vaccines in association with the occurrence of adverse events is meaningful to explore. Furthermore, the overall rates are useful for monitoring variations in adverse events rates in the general population.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20857144     DOI: 10.1007/s00431-010-1294-4

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.860


  34 in total

Review 1.  Development and clinical application of new polyvalent combined paediatric vaccines.

Authors:  F E André
Journal:  Vaccine       Date:  1999-03-26       Impact factor: 3.641

Review 2.  Combination vaccines.

Authors:  Margaret B Rennels
Journal:  Pediatr Infect Dis J       Date:  2002-03       Impact factor: 2.129

3.  The future of childhood immunizations: examining the European experience.

Authors:  Hugues Bogaerts
Journal:  Am J Manag Care       Date:  2003-01       Impact factor: 2.229

4.  Immunogenicity and safety of a combined DTaP-IPV vaccine compared with separate DTaP and IPV vaccines when administered as pre-school booster doses with a second dose of MMR vaccine to healthy children aged 4-6 years.

Authors:  Steven Black; Leonard R Friedland; Anne Schuind; Barbara Howe
Journal:  Vaccine       Date:  2006-04-21       Impact factor: 3.641

5.  Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine.

Authors:  Charles W LeBaron; Daoling Bi; Bradley J Sullivan; Carol Beck; Paul Gargiullo
Journal:  Pediatrics       Date:  2006-10       Impact factor: 7.124

6.  An explosive point-source measles outbreak in a highly vaccinated population. Modes of transmission and risk factors for disease.

Authors:  R T Chen; G M Goldbaum; S G Wassilak; L E Markowitz; W A Orenstein
Journal:  Am J Epidemiol       Date:  1989-01       Impact factor: 4.897

7.  Booster vaccination against pertussis in Chinese children at six years of age using reduced antigen content diphtheria-tetanus-acellular pertussis vaccine (Boostrix()).

Authors:  Fengcai Zhu; Shumin Zhang; Qiming Hou; Yiju Zhang; Yinghua Xu; Xiao Ma; Xidong Lu; Hongxing Pan; Dengfeng Chen; Gunasekaran Ramakrishnan; Richard Zhao; Haiwen Tang; Olivier Van Der Meeren; Hans L Bock
Journal:  Hum Vaccin       Date:  2010-03-03

8.  A comparison of booster immunisation with a combination DTPa-IPV vaccine or DTPa plus IPV in separate injections when co-administered with MMR, at age 4-6 years.

Authors:  H Marshall; T Nolan; D Roberton; P Richmond; S Lambert; J M Jacquet; L Schuerman
Journal:  Vaccine       Date:  2006-06-02       Impact factor: 3.641

9.  Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines.

Authors:  P Olin; F Rasmussen; L Gustafsson; H O Hallander; H Heijbel
Journal:  Lancet       Date:  1997-11-29       Impact factor: 79.321

10.  Comparative reactogenicity and immunogenicity of booster doses of diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine and diphtheria-tetanus-inactivated poliovirus vaccine in preadolescents.

Authors:  P C Bégué; E M Grimprel; M D Giovannangeli; V I Abitbol
Journal:  Pediatr Infect Dis J       Date:  1998-09       Impact factor: 2.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.